A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Recruiting · Phase 1 · NCT06858813
Conditions: Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $7,096
- U.S. investigators named
- 10
- Sites paid
- 9
- Planned or actual enrollment
- 232
About the trial
- Sponsor
- AbbVie
- Tested
- Lenvatinib (drug), ABBV-324 (drug)
- Dates
- Started 2025-04-14; completion 2030-09
- Results posted
- Not yet
HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events and change in disease activity when ABBV-324 is given to adult participants to treat hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). ABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms. Each arm receives ABBV-324 alone (monotherapy) or a comparator drug, lenvatinib followed by a safety follow-up period. Approximately 232 HCC or LUSC …
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $7,096 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Farshid Dayyani, M.D., PH.D. Medical Oncology · Orange, CA
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- Richard S. Finn, MD Hematology & Oncology · Santa Monica, CA
- Daneng Li, M.D. Medical Oncology · Duarte, CA
- Joseph W. Franses, MD Medical Oncology · Chicago, IL
- Benjamin R. Tan, MD Medical Oncology · Saint Louis, MO
- Ghassan K. Abou-alfa, MD Medical Oncology · New York, NY
- Daniel Lin, M.D. Medical Oncology · Philadelphia, PA
- Mirelis Acosta, M.D. Hematology & Oncology · San Juan, PR
- Meredith S. Pelster, M.D. Hematology & Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $1,670
- Sarah Cannon Research Institute $1,120
- Fundacion De Investigacion De Diego $725
- Usc Norris Comprehensive Cancer Center $670
- Uci Health-Orange, CA $615
- Resnick Neuropsychiatric Hospital at UCLA, CA $615
- Ucm Emergency Department Outpatient Pharmacy $615
- Washington University School of Medicine - St Louis $560
- Memorial Sloan Kettering Cancer Center $505
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.